GlassScriptPhysician profile
Matthew Garza
NPI 1720540081
$3,724.85
in general payments reported to CMS, 2019-2025
35 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.47 · 2020: $323 · 2021: $588 · 2022: $446 · 2023: $980 · 2024: $677 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $651.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $351.67 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $271.04 | 2020-2025 | Airsupra, Breztri |
| Genzyme Corporation | $247.81 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $227.46 | 2020-2023 | Dupixent |
| Exact Sciences Corporation | $214.15 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $136.98 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Grifols USA, LLC | $124.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.54 | 2022 | |
| Glaxosmithkline, LLC. | $117.47 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.68 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $109.38 | 2021 | |
| Csl Behring | $99.47 | 2019 | |
| Phadia US INC. | $84.20 | 2023 | Immunocap |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.20 | 2020-2021 | |
| Abbvie INC. | $70.92 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $66.33 | 2024-2025 | Voquezna |
| Pfizer INC. | $66.05 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.89 | 2023 | |
| Mylan Specialty L.P. | $49.89 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $44.55 | 2023 | Quviviq |
| Dexcom, INC. | $42.69 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $40.93 | 2022 | |
| Acorda Therapeutics, INC | $36.36 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.58 | 2022-2023 | Livalo, Seglentis |
| Daiichi Sankyo INC. | $22.34 | 2023 | Injectafer |
| Inspire Medical Systems, INC. | $21.66 | 2025 | Inspire |
| Upsher-Smith Laboratories LLC | $19.21 | 2021 | |
| Horizon Therapeutics Plc | $16.48 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $15.41 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.09 | 2023 | |
| Medicem INC. | $15.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.35 | 2021 | |
| Allergan, INC. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.